Yogesh Subramanian | Health Sciences | Best Academic Researcher Award

Published on by Research Awards

Dr. Yogesh Subramanian | Health Sciences | Best Academic Researcher Award

Madras Medical College | India 

Dr. Yogesh Subramanian, M.D., is an accomplished Senior Assistant Professor and Medical Teacher at the Institute of Internal Medicine, Madras Medical College and Rajiv Gandhi Government General Hospital (RGGGH), Chennai. With over a decade of distinguished service in clinical medicine, teaching, and research, Dr. Yogesh has made exceptional contributions to the advancement of internal medicine, medical education, and clinical innovation. He holds an M.D. in General Medicine from Stanley Medical College and an M.B.B.S. from PSG Institute of Medical Sciences, Coimbatore. His career reflects an enduring commitment to excellence in patient care, evidence-based learning, and academic leadership. Dr. Yogesh has completed more than 20 research projects and published over 34 indexed papers across reputed international databases such as PubMed, Google Scholar, and ResearchGate. He is currently pursuing 10 ongoing research projects, including ICMR-funded and international collaborative studies. His multidisciplinary research focuses on Internal Medicine, Endocrinology, Hematology, Infectious Diseases, Critical Care, and Medical Education. Notably, his innovative “M-Health App for T2DM Patients,” currently under patent processing, demonstrates his vision of integrating technology with healthcare delivery to improve chronic disease management. A passionate academician and faculty trainer, Dr. Yogesh has been actively involved in the implementation of Competency-Based Medical Education (CBME) and faculty development under the National Medical Commission (NMC) Nodal Centre. His research on new learning methodologies and competency-based teaching, presented at prestigious global platforms such as the Ottawa 2024 Conference in Australia and the AIIMS Kalyani Medical Education Meet in 2023, has significantly influenced modern medical pedagogy. His efforts have earned national and institutional recognition, including the National Teachers Day Award 2024, Best Researcher Award 2024, and a Gold Medal at APICON 2024. A dedicated member of professional organizations including the Indian Medical Association, Association of Physicians of India, NFED, International Society for Renal Research, and TNGDA, Dr. Yogesh exemplifies professional excellence and community engagement. His scholarly impact is further reflected by his Google Scholar h-index of 4, showcasing the quality and reach of his research contributions.

Profile: Google Scholar

Featured Publications

Sud, R., Agarwal, N., Aishwarya, V., Aggarwal, A., Kalawatia, M., Sangoi, R., … (2023). A case series of dengue myocarditis: A complication observed in dengue patients. Cureus, 15(11).

Nallathambi, N., & Chinnadurai, A. (2024). Carboplatin-induced hematuria with obstructive acute kidney injury. Cureus, 16(4).

Kothari, R., Johny, M. P., D., Mistry, D., Irfana, M., Yogesh, S., & Vemparala, S. S. (2024). Grip to health: Unlocking the clinical potential of isometric hand grip strength—A narrative review. Journal of Pharmacy and Bioallied Sciences, 16(Suppl 4), S3102–S3104.

Prashanth, A., Kothari, R., Yogesh, S., Mittal, G., Gheewala, S., Bokariya, P., … (2023). Examining body fat percentage, galvanic skin response, and muscle grip strength in female hypothyroid patients. Cureus, 15(7).

Mittal, G., Prashanth, A., Dhali, A., Prasad, R., Yogesh, S., Nurani, K. M., … (2025). Plant extracts with antioxidant and hepatoprotective benefits for liver health: A bibliometric analysis of drug delivery systems. World Journal of Gastroenterology, 31(18), 105836.

Chandrashekar, N. G., Murali, N. V. I., Mohammed, A. I., Hemachandran, D., … (2024). Comprehensive clinical profile and hemodialysis outcomes in patients attending a tertiary care hospital. Cureus, 16(8).

Yogesh, S., Venkatesan, S., Jayaraj, A. T., Karthigeyan, T. S., Siva Prasath, S., … (2024). Understanding the complexity of hyperglycemic emergencies: Exploring the influence of the type and duration of diabetes mellitus and its impact on mortality. Cureus, 16(4).

Yogesh, S., Nallathambi, N., Seshadri, H., Gautham, R., Naidu, S. P., Navvin, S., … (2024). Assessing the effect of the anti-tuberculosis drug rifampicin on known hypertensive patients with tuberculosis in a tertiary care center. Cureus, 16(4).

Cheng Ni | Health Sciences | Best Researcher Award | 13442

Published on by Research Awards

Prof. Cheng Ni | Health Sciences | Best Researcher Award

Prof. Cheng Ni, Cancer Hospital, Chinese Academy of Medical Sciences, China

Prof. Cheng Ni, M.D., Ph.D. is a Professor and Consultant Anesthesiologist at the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, where he also serves as Associate Chief of the Department of Anesthesiology. With extensive clinical and academic experience in thoracic anesthesiology, perioperative neuroprotection, and cancer pain management, Prof. Ni has held key roles at leading institutions including Peking University and Harvard University. His research focuses on perioperative neurocognitive disorders, tumor immunology, and the application of AI in anesthesiology. He has published over 50 SCI-indexed articles and holds 11 authorized patents.

Profile

Scopus

🎓 Early Academic Pursuits

Prof. Cheng Ni’s academic journey is a testament to dedication and intellectual rigor. He began his medical education at Capital Medical University, earning his M.D. in 2003 and M.S. in 2005, laying a solid foundation in medical sciences. His passion for deeper understanding and specialization led him to pursue a Ph.D. at Peking University, one of China’s most prestigious institutions, which he completed in 2012. This advanced academic training equipped him with a rich knowledge base in anesthesiology and related biomedical sciences, paving the way for a distinguished career in clinical practice, teaching, and research.

🩺 Professional Endeavors

Prof. Ni’s professional career reflects a steady and impactful rise through China’s top-tier medical institutions. He began as a Resident at Peking University Third Hospital (2005–2008) and subsequently served as an Attending Anesthesiologist (2008–2015). During this period, he gained hands-on clinical experience and honed his leadership abilities.

In 2013–2014, he expanded his global perspective as a Postdoctoral Research Fellow at Harvard University, engaging with cutting-edge international research. Upon his return, he held several key administrative and academic roles at Peking University, including Chief Secretary of the Faculty of Anesthesiology, and Associate Consultant and Associate Professor.

In 2020, Prof. Ni joined the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, a top national institution, as a Consultant and Associate Professor. His expertise quickly earned him leadership roles as Associate Chief of the Department of Anesthesiology, and by 2021, he was promoted to Professor and Consultant. He also became a Ph.D. Supervisor in 2023, mentoring the next generation of clinical researchers and specialists.

🔬 Contributions and Research Focus

Prof. Ni’s research contributions span multiple high-impact areas in modern anesthesiology and cancer care. His primary interests include:

  • Perioperative neurocognitive disorders 🧠

  • Thoracic anesthesiology and neuroprotection 💨🛡️

  • Cancer pain management 🧬

  • Genetics and tumor immunology 🧫

  • AI in anesthesiology research 🤖🩺

He has authored over 50 peer-reviewed articles in leading SCI-indexed journals, including Aging Cell, CNS Neuroscience & Therapeutics, Life Sciences, and Anesthesia & Analgesia. His recent publications explore the neuroinflammatory response during surgery, the effects of anesthesia on brain aging, and the integration of hybrid learning models for brain cell identification—blending medical science with artificial intelligence.

In addition to journal publications, Prof. Ni has contributed to 12 academic monographs and holds 11 authorized patents, underscoring his commitment to translational research and innovation.

🏅 Accolades and Recognition

Prof. Cheng Ni is widely respected in China’s medical and academic communities. His achievements have been recognized through his appointment to senior roles such as:

  • Chief Secretary of Anesthesiology Faculty, Peking University Health Science Center

  • Associate Chief of the Department of Anesthesiology at China’s National Cancer Center

  • Ph.D. Supervisor, guiding graduate-level research and fostering academic excellence

These appointments are not only acknowledgments of his skill and dedication but also affirmations of his influence in shaping anesthesiology and cancer care practices in China.

🌍 Impact and Influence

Prof. Ni’s work resonates far beyond the operating room. His integration of AI into anesthesiology research marks a forward-thinking approach to modern medicine. By exploring the cognitive effects of anesthesia, he contributes to improving surgical outcomes and patient safety, particularly in aging populations.

His leadership and mentorship roles at premier institutions like Peking University and the Cancer Hospital, CAMS, have helped nurture a generation of professionals equipped with both technical excellence and ethical insight.

Furthermore, his international collaboration with Harvard University has brought valuable cross-cultural research experience into Chinese clinical research settings, promoting a global standard in anesthesiology and perioperative medicine.

🌱 Legacy and Future Contributions

Looking ahead, Prof. Ni is poised to play a pivotal role in shaping the future of anesthesiology in cancer care. His continued emphasis on neuroprotection, chronic pain management, and artificial intelligence applications signals a progressive vision aligned with global health priorities.

As a Ph.D. supervisor and seasoned educator, his mentorship will continue to inspire emerging scholars. His innovations in clinical protocols and diagnostic tools will likely set new benchmarks in anesthetic safety and cancer patient recovery.

Prof. Cheng Ni stands as a bridge between tradition and innovation, combining deep clinical knowledge with research excellence to lead transformative change in anesthesiology and oncology care.

Publication Top Notes

Aged hippocampal single-cell atlas screening unveils disrupted neuroglial system in postoperative cognitive impairment

Author: Z., Suo, Zizheng, T., Xiao, Ting, Y., Qu, Yinyin, … H., Zheng, Hui, C., Ni, Cheng
Journal: Aging Cell
Year: 2025

Year: 2024

 

Ferdinando D’Amico | Medicine and Health Sciences | Best Researcher Award

Published on by Research Awards

Ferdinando D’Amico | Medicine and Health Sciences | Best Researcher Award

Dr Ferdinando D’Amico, IRCCS San Raffaele Hospital, Italy

Dr. Ferdinando D’Amico is a distinguished gastroenterologist at IRCCS San Raffaele Hospital in Milan, Italy, with expertise in gastroenterology and endoscopy. 🎓 He completed his residency in Gastroenterology/Digestive Diseases and earned his PhD at Hunimed University, focusing on histology in inflammatory bowel diseases. His academic journey includes a degree in Medicine and Surgery from “Cattolica del Sacro Cuore” University, where he researched intestinal permeability and atherosclerosis. 🏥 His training included internships in gastroenterology and cardiology at “Agostino Gemelli” Hospital in Rome. Dr. D’Amico is proficient in English and French, and skilled in digital communication. 🌍🔬

Publication profile

Scopus

Education 

🎓 From 2003 to 2008, attended Classical High School, graduating with highest honours. From 2009 to 2015, pursued a Degree in Medicine and Surgery at “Cattolica del Sacro Cuore” University, Rome, also graduating with highest honours. 🏆 The dissertation, titled “Alterations in Intestinal Permeability and Inflammation: A Novel Potential Mechanism of Atherosclerosis,” was supervised by Professor Filippo Crea. 📜 Currently registered with the Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri di Caserta, registration number 7593. 🩺

Experience

From November 1, 2016, to November 2, 2020, [Name] completed their residency in Gastroenterology/Digestive System Diseases at Hunimed University in Pieve Emanuele, Italy, graduating with highest honors. They then pursued a Ph.D. at the same institution, focusing on “The Role of Histology in Inflammatory Bowel Diseases,” under the guidance of Prof. Silvio Danese. From January 1, 2021, to February 9, 2024, they worked as a Gastroenterologist at the IRCCS San Raffaele Hospital in Milan, Italy, in the Gastroenterology and Endoscopy Unit, also directed by Prof. Silvio Danese. 🏥📚🩺

Research focus

Based on the provided publications, the research focus appears to be on inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis. The studies address various aspects such as comparing treatments (e.g., tofacitinib vs. ustekinumab), assessing remission through non-invasive methods, and evaluating regulatory guidance for JAK inhibitors. The research also explores the use of biologics and other therapies in managing IBD, including switching between different treatment forms. This indicates a strong emphasis on optimizing treatment strategies and improving patient outcomes in IBD. 🌟📚💊

Publication top notes

Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study

Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn’s disease: a prospective cohort study

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

The role of filgotinib in ulcerative colitis and Crohn’s disease

A new national survey of centers for cognitive disorders and dementias in Italy

An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study

Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn’s disease

MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations

Advancing transmural remission as a treatment target in Crohn’s disease: The future of tight-control strategy?

Noninvasive Assessment of Postoperative Disease Recurrence in Crohn’s Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease